Literature DB >> 23928963

The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome.

Rachel P J Lai1, Justine K Nakiwala, Graeme Meintjes, Robert J Wilkinson.   

Abstract

HIV-1 patients co-infected with some pathogens are at risk of developing the immune reconstitution inflammatory syndrome (IRIS) when initiating antiretroviral therapy (ART). IRIS is characterized by inflammation leading to the clinical worsening of a treated infection or the unmasking of a previously undiagnosed condition or infection. It is commonly associated with tuberculosis (TB), 8-43% of the HIV-TB co-infected patients prescribed with antitubercular treatment and ART develop TB-IRIS. Although IRIS has been recognized for over 20 years, relatively little was known until recently about its pathogenesis. Despite these advances in understanding IRIS, there remains no immune biomarker for diagnostic or prognostic purposes. Here, we review the risk factors associated with TB-IRIS, the challenges in studying this syndrome, and how T lymphocytes, dysregulated cytokine responses, and innate immunity may contribute to the development of TB-IRIS.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Drug therapy complications; HIV-1 infection; Immune reconstitution inflammatory syndrome; Tuberculosis

Mesh:

Substances:

Year:  2013        PMID: 23928963     DOI: 10.1002/eji.201343632

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

2.  Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.

Authors:  Waleed Elsegeiny; Taylor Eddens; Kong Chen; Jay K Kolls
Journal:  Infect Immun       Date:  2015-03-02       Impact factor: 3.441

Review 3.  Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge.

Authors:  Gregory P Bisson; Nicola Zetola; Ronald G Collman
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Immune reconstitution inflammatory syndrome in non-HIV cryptococcal meningitis: Cross-talk between pathogen and host.

Authors:  Ling-Hong Zhou; Hua-Zhen Zhao; Xuan Wang; Rui-Ying Wang; Ying-Kui Jiang; Li-Ping Huang; Ching-Wan Yip; Jia-Hui Cheng; Chun-Xing Que; Li-Ping Zhu
Journal:  Mycoses       Date:  2021-08-19       Impact factor: 4.931

5.  Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation.

Authors:  Ngomu Akeem Akilimali; Daniel M Muema; Charles Specht; Christina C Chang; Mahomed-Yunus S Moosa; Stuart M Levitz; Sharon R Lewin; Martyn A French; Thumbi Ndungʼu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

6.  Plasma But Not Cerebrospinal Fluid Interleukin 7 and Interleukin 5 Levels Pre-Antiretroviral Therapy Commencement Predict Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Ngomu Akeem Akilimali; Christina C Chang; Daniel M Muema; Tarylee Reddy; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  Clin Infect Dis       Date:  2017-10-16       Impact factor: 9.079

Review 7.  Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop.

Authors:  Jillian Dietzold; Archana Gopalakrishnan; Padmini Salgame
Journal:  F1000Prime Rep       Date:  2015-03-03

Review 8.  Immune reconstitution inflammatory syndrome in HIV-infected patients.

Authors:  Naomi F Walker; James Scriven; Graeme Meintjes; Robert J Wilkinson
Journal:  HIV AIDS (Auckl)       Date:  2015-02-12

Review 9.  Towards tuberculosis elimination: an action framework for low-incidence countries.

Authors:  Knut Lönnroth; Giovanni Battista Migliori; Ibrahim Abubakar; Lia D'Ambrosio; Gerard de Vries; Roland Diel; Paul Douglas; Dennis Falzon; Marc-Andre Gaudreau; Delia Goletti; Edilberto R González Ochoa; Philip LoBue; Alberto Matteelli; Howard Njoo; Ivan Solovic; Alistair Story; Tamara Tayeb; Marieke J van der Werf; Diana Weil; Jean-Pierre Zellweger; Mohamed Abdel Aziz; Mohamed R M Al Lawati; Stefano Aliberti; Wouter Arrazola de Oñate; Draurio Barreira; Vineet Bhatia; Francesco Blasi; Amy Bloom; Judith Bruchfeld; Francesco Castelli; Rosella Centis; Daniel Chemtob; Daniela M Cirillo; Alberto Colorado; Andrei Dadu; Ulf R Dahle; Laura De Paoli; Hannah M Dias; Raquel Duarte; Lanfranco Fattorini; Mina Gaga; Haileyesus Getahun; Philippe Glaziou; Lasha Goguadze; Mirtha Del Granado; Walter Haas; Asko Järvinen; Geun-Yong Kwon; Davide Mosca; Payam Nahid; Nobuyuki Nishikiori; Isabel Noguer; Joan O'Donnell; Analita Pace-Asciak; Maria G Pompa; Gilda G Popescu; Carlos Robalo Cordeiro; Karin Rønning; Morten Ruhwald; Jean-Paul Sculier; Aleksandar Simunović; Alison Smith-Palmer; Giovanni Sotgiu; Giorgia Sulis; Carlos A Torres-Duque; Kazunori Umeki; Mukund Uplekar; Catharina van Weezenbeek; Tuula Vasankari; Robert J Vitillo; Constantia Voniatis; Maryse Wanlin; Mario C Raviglione
Journal:  Eur Respir J       Date:  2015-04       Impact factor: 16.671

10.  Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome.

Authors:  Justine K Nakiwala; Naomi F Walker; Collin R Diedrich; William Worodria; Graeme Meintjes; Robert J Wilkinson; Harriet Mayanja-Kizza; Robert Colebunders; Luc Kestens; Katalin A Wilkinson; David M Lowe
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.